...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy
【24h】

Hsp 70/Hsp 90 organizing protein as a nitrosylation target in cystic fibrosis therapy

机译:Hsp 70 / Hsp 90组织蛋白在囊性纤维化治疗中作为亚硝化靶标

获取原文
获取原文并翻译 | 示例
           

摘要

The endogenous signaling molecule S-nitrosoglutathione (GSNO) and other S-nitrosylating agents can cause full maturation of the abnormal gene product △F508 cystic fibrosis (CF) transmembrane conductance regulator (CFTR). However, the molecular mechanism of action is not known. Here we show that Hsp70/Hsp90 organizing protein (Hop) is a critical target of GSNO, and its S-nitrosylation results in AF508 CFTR maturation and cell surface expression. S-nitrosylation by GSNO inhibited the association of Hop with CFTR in the endoplasmic reticulum. This effect was necessary and sufficient to mediate GSNO-induced cell-surface expression of △F508 CFTR. Hop knockdown using siRNA recapitulated the effect of GSNO on △F508 CFTR maturation and expression. Moreover, GSNO acted additively with decreased temperature, which promoted mutant CFTR maturation through a Hop-independent mechanism. We conclude that GSNO corrects △F508 CFTR trafficking by inhibiting Hop expression, and that combination therapies-using differing mechanisms of action-may have additive benefits in treating CF.
机译:内源性信号分子S-亚硝基谷胱甘肽(GSNO)和其他S-亚硝基化剂可导致异常基因产物△F508囊性纤维化(CF)跨膜电导调节剂(CFTR)完全成熟。然而,作用的分子机理尚不清楚。在这里,我们显示Hsp70 / Hsp90组织蛋白(Hop)是GSNO的关键目标,其S-亚硝基化可导致AF508 CFTR成熟和细胞表面表达。 GSNO进行的S-亚硝基化抑制了内质网中Hop与CFTR的结合。该作用对于介导GSNO诱导的△F508 CFTR的细胞表面表达是必要和充分的。使用siRNA进行的蛇麻草敲除可以概括GSNO对△F508 CFTR成熟和表达的影响。此外,GSNO在降低的温度下具有加性作用,这通过独立于Hop的机制促进了突变体CFTR的成熟。我们得出的结论是,GSNO通过抑制Hop表达来纠正△F508 CFTR转运,并且使用不同作用机制的联合疗法在治疗CF中可能具有附加益处。

著录项

  • 来源
  • 作者单位

    Department of Pediatric Respiratory Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908;

    rnDepartment of Pediatric Respiratory Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908;

    rnDepartment of Pediatric Respiratory Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908;

    rnDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA 22908;

    rnDepartment of Pediatric Respiratory Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908;

    rnDepartment of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261;

    rnDepartment of Biochemistry and Biophysics, Texas A&M University, College Station, TX 77843;

    rnWashington University Proteomics Center, St. Louis, MO 63108-2259;

    rnWashington University Proteomics Center, St. Louis, MO 63108-2259;

    rnWashington University Proteomics Center, St. Louis, MO 63108-2259;

    rnDepartment of Pediatric Respiratory Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908;

    rnDepartment of Medicine, University of North Carolina, Chapel Hill, NC 27599;

    rnDepartment of Medicine, University of North Carolina, Chapel Hill, NC 27599;

    rnDepartment of Pediatric Respiratory Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908;

    rnDepartment of Pediatric Respiratory Medicine, University of Virginia School of Medicine, Charlottesville, VA 22908;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    cystic fibrosis transmembrane conductance regulator; S-nitrosoglutathione corrector I treatment;

    机译:囊性纤维化跨膜电导调节剂S-亚硝基谷胱甘肽校正剂I治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号